Cargando…
Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2
Myotonic dystrophy is an autosomal dominant, multisystem disorder that is characterized by myotonic myopathy. The symptoms and severity of myotonic dystrophy type l (DM1) ranges from severe and congenital forms, which frequently result in death because of respiratory deficiency, through to late-onse...
Autores principales: | Kamsteeg, Erik-Jan, Kress, Wolfram, Catalli, Claudio, Hertz, Jens M, Witsch-Baumgartner, Martina, Buckley, Michael F, van Engelen, Baziel G M, Schwartz, Marianne, Scheffer, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499739/ https://www.ncbi.nlm.nih.gov/pubmed/22643181 http://dx.doi.org/10.1038/ejhg.2012.108 |
Ejemplares similares
-
EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency
por: Baumgartner-Parzer, Sabina, et al.
Publicado: (2020) -
Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017) -
High disease impact of myotonic dystrophy type 2 on physical and mental functioning
por: Tieleman, Alide A., et al.
Publicado: (2011) -
Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1
por: Nieuwenhuis, Sylvia, et al.
Publicado: (2019) -
Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy
por: van As, Daniël, et al.
Publicado: (2021)